Table 1.
Summary of clinicopathological variables of the three patient cohorts.
| Clinical variables | Training set D1 (UH) N(%) | Validation set D2 (ECOG) N(%) | Validation set D3 (TMC) N(%) |
|---|---|---|---|
| No of patients | 116 | 121 | 84 |
| Age | 59.7 ± 10.4 | 50.0 ± 8.8 | 50.4 ± 10.4 |
| ≥50 years | 99(85%) | 63(52%) | 40(48%) |
| <50 years | 17(15%) | 58(48%) | 44(52%) |
| Race | |||
| Non-Hispanic white | 89(77%) | 112(93%) | 0(0%) |
| Non-Hispanic black | 26(22%) | 3(2%) | 0(0%) |
| South Asian | 0(0%) | 0(0%) | 84(100%) |
| Other | 1(1%) | 6(5%) | 0(0%) |
| PR status | |||
| Positive | 98(84%) | 105(87%) | 72(86%) |
| Negative | 17(15%) | 16(13%) | 12(14%) |
| Unknown | 1(1%) | 0(0%) | 0(0%) |
| HER2 status | |||
| Positive | 1(0.9%) | 24(20%) | 0(0%) |
| Negative | 112(96.5%) | 51(42%) | 84(100%) |
| Unknown | 3(2.6%) | 46(38%) | 0(0%) |
| Histologic grade | |||
| Grade 1 | 26(22%) | 15(12.4%) | 1(1%) |
| Grade 2 | 72(62%) | 57(47.1%) | 30(36%) |
| Grade 3 | 18(16%) | 33(27.3%) | 53(63%) |
| Unknown | 0(0%) | 16(13.2%) | 0(0%) |
| Tumor size | |||
| ≤20 mm | 75(65%) | 65(54%) | 17(20%) |
| >20 mm | 40(34%) | 55(45%) | 60(72%) |
| Unknown | 1(1%) | 1(1%) | 7(8%) |
| Chemotherapy | |||
| Yes | 32(28%) | 121(100%) | 57(68%) |
| No | 82(71%) | 0(0%) | 6(7%) |
| Unknown | 2(1%) | 0(0%) | 21(25%) |
| Event status | |||
| Event | 22(19%) | 23(19%) | 21(25%) |
| Censored | 90(78%) | 98(81%) | 51(61%) |
| Unknown | 4(3%) | 0(0%) | 12(14%) |